Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 14, 2008

SAFC Moves to Increase Biologics Production Capacity

  • SAFC plans a $12 million expansion at its biologics production facility in Carlsbad, CA. Two fully segregated viral product manufacturing suites will be built. They will enable an increase in SAFC Pharma’s viral manufacturing capacity to commercial-scale quantities, explains vp of manufacturing and U.S. operations, David Feldker.

    Due to become operational in the second half of 2009, the new facilities will add 8,000 sq. ft. of manufacturing space and enable 100 L batch production in stirred tank bioreactors and 1,000 L batch manufacturing in disposable bioreactors, continues Feldker.

    The expansion will add to the current 44,000 sq. ft. site and be Biosafety Level 2 compliant, allowing manipulation of human pathogens.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »